Open an account

American Oriental Bioengineering

AOBI · OTC

$0.013+$0.0022 (+20.37%)TodayMarket closed ·
No price history for this range.

About AOBI

American Oriental Bioengineering, Inc. engages in the development, manufacture, and commercialization of pharmaceutical and healthcare products. The firm is engaged in development, manufacture and commercialization of a broad range of pharmaceutical and healthcare products. The Company’s business consists of prescription pharmaceutical products, over-the-counter pharmaceutical products and nutraceutical products. Two flagship prescription pharmaceutical products marketed in China are Shuanghuanglian Lyophilized Injection Powder, or SHL Injection Powder, and Cease Enuresis Soft Gel, or CE Gel. Over-the-counter pharmaceutical products are similar to its prescription pharmaceutical products in that they need approval from the SFDA. Nutraceutical products are intended for the overall well-being. The firm also sells several nutraceutical products, including its soybean peptide-based drinks, tablets, powder and instant coffee.

Employees
4,295
Headquarters
Shenzhen, Guangdong
Listed
Dec 18, 2006
Sector
Consumer Staples
Industry
Personal Care Products
Website
bioaobo.com

AOBI key statistics

Market cap
949
Price-earnings ratio
0.00
Dividend yield
—
Average volume
204
Volume
1
Open price
$0.013
High today
$0.013
Low today
$0.013
52 Week high
$0.013
52 Week low
$0.0011

American Oriental Bioengineering (AOBI) at a glance

American Oriental Bioengineering (AOBI) last traded at $0.013, with a market cap of 949 and a price-to-earnings ratio of 0.00.

Volume so far is 1 shares, below the average of 204 shares a day.

Over the past year American Oriental Bioengineering has ranged from $0.0011 to $0.013, and now sits 100% of the way up that range.

American Oriental Bioengineering met or beat analyst EPS estimates in 1 of the last 8 quarters. In Q3 FY11 it reported $80.16 per share against an estimate of $51.10.

AOBI earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 1 of the last 8 quarters, by 56.9% on average.

  1. Q4 FY09: reported $140.28 per share against an estimate of $163.53
  2. Q1 FY10: reported $40.08 per share against an estimate of $64.73
  3. Q2 FY10: reported $70.14 per share against an estimate of $104.76
  4. Q3 FY10: reported $70.14 per share against an estimate of $81.76
  5. Q4 FY10: reported $40.08 per share against an estimate of $85.17
  6. Q1 FY11: reported $10.02 per share against an estimate of $35.77
  7. Q2 FY11: reported $50.10 per share against an estimate of $71.54
  8. Q3 FY11: reported $80.16 per share against an estimate of $51.10

Similar companies

Companies in the same industry as American Oriental Bioengineering

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.